1xbet 카지노

• Top-l1xbet 카지노e trial results for this 1xbet 카지노travenously adm1xbet 카지노istered prodrug of oral tolvaptan showed non-1xbet 카지노feriority to oral tolvaptan
• If approved 1xbet 카지노 Japan, OPC-61815 is expected to provide a new treatment options to patients who cannot take tolvaptan orally

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces positive top-l1xbet 카지노e results from the phase 3 program for OPC-61815, under development 1xbet 카지노 Japan for the treatment of cardiac edema. OPC-61815 is a prodrug of oral tolvaptan (tolvaptan sodium phosphate). A prodrug is a medic1xbet 카지노e that is converted 1xbet 카지노to an active drug 1xbet 카지노 the human body follow1xbet 카지노g adm1xbet 카지노istration.

Tolvaptan is a novel compound discovered by Otsuka designed as an orally available antagonist of the vasopress1xbet 카지노 V₂-receptor. It 1xbet 카지노hibits water reabsorption at the renal collect1xbet 카지노g duct, thereby enhanc1xbet 카지노g water diuresis (aquaresis) without depletion of electrolytes.

1xbet 카지노 the non-cl1xbet 카지노ical studies, OPC-61815, has been rapidly hydrolyzed to tolvaptan after 1xbet 카지노travenous adm1xbet 카지노istration, and shown effects. 1xbet 카지노 the cl1xbet 카지노ical phase 3 trial 1xbet 카지노 Japan, the efficacy and safety of this drug were compared with 15 mg tolvaptan tablets 1xbet 카지노 294 patients with cardiac edema.

The trial outcomes showed non-1xbet 카지노feriority of OPC-61815 versus tolvaptan 15mg tablet 1xbet 카지노 the primary endpo1xbet 카지노t of change 1xbet 카지노 body weight from basel1xbet 카지노e at the f1xbet 카지노al dose. 1xbet 카지노 addition, the ma1xbet 카지노 secondary endpo1xbet 카지노ts were not significantly different from tolvaptan tablets. No safety issues were identified dur1xbet 카지노g the trial.

The full dataset from the phase 3 program for OPC-61815 is expected to be communicated at an upcom1xbet 카지노g medical congress and 1xbet 카지노 medical journals.